HealthUSA

US approved injectable anti-HIV drug

The Financial Times, citing data from British drugmaker GlaxoSmithKline (GSK), reports that the Food and Drug Administration has approved the first injectable drug Apritode to prevent HIV infection.

The publication states that the drug’s manufacturer is ViiV Healthcare, which owns GSK.
He needs to have aperitoneal injections six times a year, while his current Pre-Exposure Prevention (PREP) regimen includes daily pills.

Debra Berncrant, director of antiviral drugs at the Food and Drug Administration’s Center for Drug Evaluation and Research, told the Financial Times that Apritode will play an important role in infection control in the United States, and the drug will help people at high risk of infection and certain groups. Since they cannot take medicine every day.

According to GSK, the retail price for Abritod will be $3.7 thousand per syringe. The company expects to apply for UK and EU registration next year.

Related Articles

Leave a Reply

Back to top button